₹178.03
−7.98%NSE close, 16 Nov 2026
−28.01%
Wanbury is a small cap company, listed on NSE under the symbol WANBURY. At ₹178.03 a share, the market values the whole company at ₹623 crore.
In FY26, it reported sales of ₹650 crore and a net profit of ₹66 crore, an operating margin of 16.4%. Over the last three years, sales grew 9.2% a year.
The market values the company at 12.5 times its profit over the last twelve months and 3.97 times its book value; its return on equity is 31.7% and its borrowings are 1.42 times its equity.
Promoters hold 42.98% of the shares, and have pledged 5.5% of their holding. Foreign institutions hold 0.71%, and domestic institutions, mutual funds among them, 0.02%.
Over the past year the share price has fallen 29.8%, and it is 50.4% below its 52-week high.
₹ crore. Consolidated figures where the company filed them, standalone otherwise (marked S).
Clarifications on investor queries regarding recent announcement
Wanbury Limited s Tanuku Plant US FDA Inspection Updates
Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HCl EP grade
Press release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026
The financial results for the period ended September 30, 2026.
| Dec 2025 S |
|---|
| Mar 2026 S |
|---|
| Jun 2026 S |
|---|
| Sep 2026 |
|---|
| Sales | 146 | 139 | 131 | 161 | 133 | 172 | 163 | 160 | 162 | 165 | 166 | 183 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 124 | 121 | 120 | 141 | 119 | 142 | 139 | 134 | 136 | 135 | 149 | 160 |
| Operating profit | 21.2 | 18.2 | 11.0 | 20.0 | 14.0 | 29.6 | 24.4 | 25.8 | 26.7 | 29.9 | 16.2 | 22.7 |
| Operating margin | 14.5% | 13.0% | 8.4% | 12.4% | 10.5% | 17.2% | 15.0% | 16.1% | 16.4% | 18.1% | 9.8% | 12.4% |
| Other income | 0.7 | 0.9 | 0.9 | 1.6 | 0.8 | 1.8 | 0.4 | 0.2 | 0.2 | 0.2 | 0.4 | 0.1 |
| Interest | 8.3 | 7.5 | 7.6 | 10.2 | 10.2 | 9.0 | 7.5 | 7.1 | 7.3 | 8.1 | 8.0 | 6.3 |
| Depreciation | 3.3 | 3.3 | 3.3 | 3.3 | 3.3 | 3.4 | 3.6 | 3.7 | 3.7 | 3.2 | 4.0 | 4.2 |
| Profit before tax | 10.3 | 33.9 | 1.0 | 8.2 | 1.3 | 19.1 | 13.6 | 15.2 | 15.9 | 15.2 | 4.6 | 12.4 |
| Tax | −0.0 | 0.3 | 0 | 0.2 | 0.1 | −1.2 | 0.1 | −0.0 | 0.1 | −6.5 | 1.3 | 3.8 |
| Net profit | 10.3 | 33.6 | 1.0 | 8.0 | 1.2 | 20.3 | 13.5 | 15.2 | 15.8 | 21.7 | 3.2 | 9.1 |
| EPS (₹) | 3.13 | 12.75 | 0.32 | 2.44 | 0.76 | 6.18 | 4.12 | 4.58 | 4.52 | 7.33 | 0.93 | 2.44 |
₹ crore, financial years to March.
| Line | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 S |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 374 | 374 | 374 | 367 | 393 | 511 | 500 | 576 | 600 | 650 |
| Expenses | 442 | 442 | 442 | 344 | 375 | 476 | 476 | 506 | 523 | 544 |
| Operating profit | −67.5 | −67.5 | −67.9 | 23.5 | 18.0 | 35.3 | 23.2 | 70.0 | 76.3 | 107 |
| Operating margin | -18.0% | -18.0% | -18.2% | 6.4% | 4.6% | 6.9% | 4.6% | 12.2% | 12.7% | 16.4% |
| Other income | 76.1 | 76.1 | 76.7 | 1.1 | 2.4 | 1.5 | 0.9 | 3.0 | 3.5 | 0.9 |
| Interest | 30.7 | 30.7 | 30.9 | 32.9 | 23.1 | 20.6 | 21.4 | 29.2 | 37.0 | 30.0 |
| Depreciation |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
| Line | FY22 | FY25 | FY26 | 6M to Sep 2026 |
|---|---|---|---|---|
| From operations | 37.6 | 26.1 | 31.5 | 37.5 |
| From investing | 0.6 | −51.2 | −56.4 | −22.7 |
| From financing | −25.6 | 25.7 | 22.4 | −8.5 |
| Spent on fixed assets | 0 | −49.0 | −59.1 | −26.6 |
| Free cash flow | 37.6 | −22.9 | −27.5 | 10.9 |
Margins, returns, debt, tax and cash.
| Line | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net margin | -8.6% | -8.6% | -8.6% | 17.5% | -3.2% | 15.9% | -2.1% | 9.7% | 5.1% | 10.2% |
| Operating margin | -18.0% | -18.0% | -18.2% | 6.4% | 4.6% | 6.9% | 4.6% | 12.2% | 12.7% | 16.4% |
| Return on equity | – | – | – | – | – | – | – | 200.3% | 51.5% | 45.8% |
| Return on capital employed | – | – | – | – | – | – | – | 62.0% | 28.6% | 24.9% |
| Return on assets | – | – | – | – | – | – | -3.4% | 16.3% | 7.4% | 12.8% |
| Debt to equity | – | – | – | – | – | – | – | 3.94 | 2.92 | 1.49 |
| Interest coverage | -0.10 | -0.10 | -0.00 | 3.00 | 0.50 | 4.90 | 0.50 | 2.90 | 1.80 | 3.00 |
| Debt to assets | – | – | – | – | – | – | 0.21 | 0.32 | 0.42 | 0.42 |
| Current ratio | – | – | – | – | – | – | 0.38 | 0.74 | 1.11 | 1.19 |
| Quick ratio | – | – | – | – | – | – | 0.31 | 0.58 | 0.89 | 0.93 |
| Cash ratio | – | – | – | – | – | – | 0.00 | 0.02 | 0.02 | 0.01 |
| Asset turnover | – | – | – | – | – | – | 1.64 | 1.68 | 1.45 | 1.26 |
| Fixed asset turnover | – | – | – | – | – | – | 3.30 | 3.86 | 3.16 | 2.87 |
| Inventory turnover | – | – | – | – | – | – | – | 8.40 | 7.80 | 5.50 |
| Receivables turnover | – | – | – | – | – | – | 7.40 | 6.40 | 5.30 | 4.50 |
| Gross margin | – | – | – | – | – | – | – | 47.4% | 50.9% | 57.5% |
| Cash from operations to profit | – | – | – | – | – | 46.0% | – | – | 85.0% | 48.0% |
| Effective tax rate | – | – | – | 0.3% | – | – | – | 0.7% | – | – |
Wanbury Limited Receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials
Wanbury Limited Awards for Tanuku and Patalganga Facilities
Wanbury Limited Regulatory Progress in API Business, New Business Opportunities and Operational Achievements
A revised press release dated October 12, 2026, titled "Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoft baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.
Press Release - Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoft baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment
Press Release regarding filing new Drug Master File (DMF) in South Africa for Tramadol HC1 API
A copy Srutinizers report of Annual General Meeting held on September 24, 2026. Further, the company has informed the Exchange regarding voting results.
Proceedings of Annual General Meeting held on September 24, 2026
Record date for the purpose of Meeting is 18-Sep-2026.
| 10.3 |
| 10.3 |
| 9.7 |
| 9.8 |
| 11.5 |
| 12.4 |
| 13.0 |
| 13.3 |
| 14.3 |
| Profit before tax | −32.4 | −32.4 | −32.4 | 64.7 | −12.4 | 81.1 | −10.3 | 56.4 | 29.6 | 59.8 |
|---|
| Tax | −0.4 | −0.4 | −0.4 | 0.2 | 0.2 | −0.4 | 0.1 | 0.4 | −1.0 | −6.3 |
|---|
| Net profit | −32.0 | −32.0 | −32.0 | 64.5 | −12.6 | 81.5 | −10.4 | 56.0 | 30.5 | 66.1 |
|---|
| EPS (₹) | -13.49 | -13.49 | -13.49 | 26.90 | -5.04 | 26.88 | -2.69 | 19.56 | 9.32 | 20.55 |
|---|